Solriamfetol (obligation for benefit assessment for the first time: excessive daytime sleepiness (EDS) with obstructive sleep apnoea (OSA) after previous therapy)


  • Active Substance: Solriamfetol
  • Name: Sunosi®
  • Therapeutic area: Obstructive sleep apnoea (OSA)
  • Pharmaceutical company: Jazz Pharmaceuticals Ireland Ltd.

Time table:

  • Start: 01.10.2021
  • Final decision by G-BA: 18.03.2022

Final decision:

  • No additional benefit proved